Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EPS (Basic) (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of EPS (Basic) data on record, last reported at -$0.98 in Q3 2025.

  • For Q3 2025, EPS (Basic) fell 32.43% year-over-year to -$0.98; the TTM value through Sep 2025 reached -$3.5, down 148.88%, while the annual FY2024 figure was -$2.55, 69.82% up from the prior year.
  • EPS (Basic) reached -$0.98 in Q3 2025 per DNTH's latest filing, down from -$0.88 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $8.95 in Q4 2023 and bottomed at -$31.62 in Q4 2022.
  • Average EPS (Basic) over 4 years is -$3.66, with a median of -$0.82 recorded in 2024.
  • The widest YoY moves for EPS (Basic): up 138.54% in 2023, down 4289.66% in 2023.
  • A 4-year view of EPS (Basic) shows it stood at -$31.62 in 2022, then skyrocketed by 128.3% to $8.95 in 2023, then tumbled by 109.16% to -$0.82 in 2024, then dropped by 19.51% to -$0.98 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.98 in Q3 2025, -$0.88 in Q2 2025, and -$0.82 in Q1 2025.